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Abstract
Purpose of Review This study is to highlight recent discover-
ies associated with the role of calcitonin peptide family and
their receptors in prostate cancer progression and bone
metastasis.
Recent Findings Studies have linked adrenomedullin (AM),
calcitonin (CT) and calcitonin gene-related peptide (CGRP) to
the spread of prostate tumours to the bone. AM can induce a
metastatic phenotype in prostate cancer cells through its action
on TRPV2 calcium channels and is also capable of influenc-
ing localised levels of RANKL in the bone to favour
tumourigenesis. CT utilises A-kinase anchoring proteins to
indirectly act on PKA and promote metastasis in prostate can-
cer. The receptor for CT contains a PDZ-binding domain, the
deletion of which stops metastasis to the bone in orthotopic
prostate models.
Summary Recent findings show strong evidence for the role
of calcitonin peptides and receptors in prostate cancer and
bone metastasis. Further research could provide potential
prognostic markers and therapeutic targets for prostate cancer
patients.
Keywords Prostate cancer . Bonemetastasis . Calcitonin
peptides . Adrenomedullin . Receptor activitymodifying
proteins . Bonemicroenvironment
Introduction
The calcitonin family of peptides all share structural similari-
ties with calcitonin (CT), a hypocalcemic hormone secreted
from the thyroid gland. Calcitonin gene-related peptide
(CGRP) is named appropriately as it is an alternative splicing
of CT gene. Amylin is another peptide in this family, sharing
40% amino acid identity with CGRP. It was first isolated from
amyloid deposits in the pancreas of Type 2 diabetes patients
and is co-secreted with insulin in β-islet cells. In addition to
their structural similarity, amylin and CGRP also have hypo-
calcemic effects [1]. Another member of this peptide family is
adrenomedullin (AM) which was first described in 1993 when
identified in a human pheochromocytoma patient [2]. It is a
potent vasodilator, acting directly on renal, cerebral and lung
circulation systems as well as the vascular supply of the bone.
Adrenomedullin 2 (also known as intermedin) has only re-
cently been identified and appears to have similar physiolog-
ical effects to those of AM [3].
The receptors for these peptides are unusual in that they are
formed by two separate proteins, a seven-transmembrane do-
main G protein-coupled receptor and a receptor activity mod-
ifying protein (RAMP). The GPCR may be either the calcito-
nin receptor (CTR) or calcitonin-like receptor (CLR) with one
of the three RAMPs (Table 1). The CTR was first cloned in
1991, with a sequence homologous to class II GPCRs, a group
including peptides such as parathyroid hormone (PTH) and
parathyroid hormone-related peptide (PTHrP). The CLR was
then later identified with high homology to CTR. RAMP1was
discovered to co-express with CLR forming the receptor for
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CGRP and RAMPs 2 and 3 couple with CLR to form two
distinct AM receptors (AM1 and AM2). RAMPs have been
found to share 30% amino acid sequence identity, and when
expressed with CTR, they form three different amylin recep-
tors [1]. Interestingly, RAMPs 2 and 3 have also been shown
to interact with PTH1 and PTH2 receptors at the cell surface
[4]. In primary mouse osteoblasts, there is evidence that PTH
can induce RAMP3 mRNA expression through the cAMP-
PKA pathway, commonly used by GPCRs [5].
The calcitonin family and their receptors have a wide range
of physiological and pathological functions which have been
widely discussed in the literature [6–9]. Due to their well-
established roles in vital cellular mechanisms, it is unsurpris-
ing that they also feature as promoters of tumourigenesis
across many different cancer types. For many years, the CT-
CTR axis has been shown to be important in many malignant
diseases. Activation of this axis stimulates invasion, angiogen-
esis, chemoresistance andmetastasis in many cancer cell lines.
Calcitonin and its receptor has been often linked in the litera-
ture with prostate cancer specifically [10–13]. Retrospective
studies have found that although advanced prostate cancer can
metastasize to various sites, the most common is the bone.
Ninety percent of patients who die from prostate cancer have
bonemetastases and there is evidence that approximately 50%
of those patients survive only 30–35 months after diagnosis
[14].
There is currently a lack of clinically useful biomarkers that
can predict bone metastasis in prostate cancer and few thera-
pies that can prevent tumour growth in this environment. Once
bone metastases have been established, prostate cancer is con-
sidered incurable. Current investigations that aim to prevent
these metastases require an understanding of two key contrib-
utors: the metastasis-initiating cancer cells (the Bseeds^) and
the bone microenvironment which can support these cells (the
Bsoil^) [15]. The relationship between the calcitonin peptide
family and prostate cancer metastasis is a novel research topic,
and it is therefore apt to appraise recent discoveries in the
involvement of these peptides in prostate cancer metastasis-
initiating cells and their possible roles in regulating the bone
microenvironment. In this review, we will first highlight stud-
ies investigating members of the calcitonin peptide family in
prostate cancer and their role in metastasis, before focusing on
the inf luence of these pept ides within the bone
microenvironment.
The Role of the Calcitonin Family in Cancer
and Metastasis
The calcitonin family of peptides have been linked with can-
cer in many studies since their first discovery. Calcitonin and
its receptor have long been implicated in prostate cancer since
it was found in 1992, that the number of cells expressing CT
increases with prostate cancer progression [16]. Further inves-
tigations have found that the CT-CTR axis is important in
prostate cancer for growth, invasion and inducing EMT. A
decade after these initial findings, studies were also able to
show the role of CT and its receptor in promoting metastasis
in prostate cancer [12]. Data shows that CT is secreted from
the prostate epithelium and is increased sevenfold in malig-
nant prostate tissues compared with benign. CT can promote
prostate cancer cell growth via adenylyl cyclase and calcium/
phospholipid pathways and can also increase invasion of cells
in vitro [11].
Investigative studies of AM have been ongoing for more
than 20 years and have demonstrated this multifunctional pep-
tide to be significantly involved in the tumourigenesis inmany
different cancer types [6]. AM is not only upregulated in can-
cer cells but also promotes angiogenesis in hypoxic conditions
and prevents apoptosis whilst also suppressing the immune
system [17, 18]. Studies have also linked AM to the role of
progressing tumours to bone metastasis; this could be antici-
pated when coupled with AM’s effect on bone physiology
which will be detailed subsequently [19]. Unsurprisingly,
AM2 has been found to be implicated in cancer progression
most recently in breast and prostate; however, mechanisms
remain relatively unclear. AM2 can stimulate cell migration
and tube formation in angiogenesis in vitro models and is also
upregulated in hypoxic conditions [20, 21]. CGRP and its
receptors have also been linked with the upregulation of sur-
vival pathways. Several studies have found CGRP to increase
proliferation by triggering the MAPK pathway [22]. Amylin
is upregulated in pancreatic cancer and is seen to increase in
diabetic patients with pancreatic cancer and continue to in-
crease in pancreatic patients with normal glucose levels; how-
ever, its role in other cancers has not been further investigated
[23].
Prostate Cancer and Metastasis: Adrenomedullin
One of the key processes in tumour metastasis is cell migra-
tion; many components of this mechanism are regulated by
intracellular calcium (Ca2+) levels. Ca2+ entry is often induced
Table 1 Receptors for calcitonin family peptides
Ligand Receptor Components
Calcitonin CTR CTR
Calcitonin gene-related peptide CGRP CLR + RAMP1
Adrenomedullin AM1 CLR + RAMP2
Adrenomedullin AM2 CLR + RAMP3
Amylin AMY1 CTR + RAMP1
Amylin AMY2 CTR + RAMP2
Amylin AMY3 CTR + RAMP3
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via ion channels, some of which are called Btransient receptor
potential^ (TRP) channels. These have been reported to be
implicated in tumourigenesis, and more specifically, the
TRPV2 channel has been found to promote the progression
of prostate cancer towards a more aggressive phenotype by
stimulating migration and invasion in cells [24]. A recent
study has found a role for AM in stimulating TRPV2 and
indirectly promoting tumour progression and metastasis.
Treatment of AM to various prostate cancer cell lines results
in phosphorylation of β1 integrin and Focal Adhesion Kinase
(FAK). This downstream response is consistent with the abil-
ity of AM to increase the invasive and migratory capacity of
prostate cancer cells by approximately 50%. siRNA knock-
down of TRPV2 in these cells abolishes all effects seen by
AM treatment leading to the conclusion that this Ca2+ channel
is regulated by AM and helps to promote prostate cancer cells
to require a metastatic phenotype [25•].
A polyclonal antibody designed to block all the receptor
components of AM (RAMP2, RAMP3 and CLR) was used to
treat prostate cancer cells in vitro resulting in a dose-
dependent reduction in proliferation and a 95% decrease in
invasion. DU145, a prostate cancer cell line with moderate
metastatic capability, was used in a mouse xenograft model.
After anti-AM treatment, tumour weight was reduced fourfold
with no metastases found. Compared with controls which
showed the presence of metastasis in the lung, kidney and
spleen, this shows that AM has a strong effect on prostate
tumour metastasis. The blocking of AM also caused a reduc-
tion in the lymphatic vasculature of the tumours but not the
surrounding tissue. This finding is very important when con-
sidering the use of AM antagonists in therapeutic intervention
of prostate cancer and bone metastasis. To further investigate
this, the group, cultured smooth muscle cells (SMCs) with
conditioned media from lymphatic endothelial cells, resulting
in SMC migration. This effect could then be reversed when
blocking AM, suggesting its role in SMC recruitment may
drive vessel formation in prostate cancer tumours [26]. This
is an interesting role for AMwhich has already been implicat-
ed in angiogenesis in different cancer types [27–29] but now is
found to capable of promoting tumour lymphangiogenesis.
Breast cancer is another highly aggressive and metastatic
disease and there have been recent studies of AM in breast
cancer metastasis which may shed light on mechanisms that
are shared in prostate cancer as well. Lysyl oxidase (LOX) is
an enzyme that can form bonds between collagen and elastin
fibrils, to ensure extracellular matrices are formed stably.
LOXL2 can contribute to tumour expression by inducing an
epithelial-to-mesenchymal transition (EMT) in cells, an event
that is vital for tumours to become metastatic. Recently, a link
between LOXL2 and RAMP3 expression has been found in
many different cancer cell lines including MDA-MB-231, a
metastatic breast cancer cell line. The inhibition of LOXL2
with shRNA caused a mesenchymal-to-epithelial transition in
breast cancer cells and a reduced invasive phenotype; these
effects were then reversed using recombinant RAMP3.
RAMP3 expression was observed to decrease with LOXL2
inhibition suggesting a regulatory role for the enzyme.
RAMP3 inhibition resulted in reduced tumour development
in vivo, with a lower tumour microvessel density compared
with controls [30]. This study shows that RAMP3 may be
specifically involved in many processes key for cancer metas-
tasis and LOXL2 stimulates these actions upstream.
It is clear looking at recent discoveries that AMhas a role to
play in prostate cancer and bone metastasis, so it would be
wise to also consider AM2 which has already been shown to
have similar physiology functions. However, this peptide has
only recently been investigated in cancers including colorec-
tal, breast and prostate [31–33]. Plasma AM2 levels were
shown to strongly correlate with many prognostic factors used
to assess prostate cancer patients including a 5-year metasta-
sis, Gleason’s score and tumour node metastasis [33].
Consequently, future investigations may regard AM2 as a po-
tential key player in prostate cancer and bone metastasis.
Prostate Cancer and Metastasis: Calcitonin
Calcitonin was shown in studies conducted almost a decade
ago, that it may have a role to play in the metastasis of prostate
cancer; however, not until recently, the mechanisms behind
this have been investigated in depth.
It is known that many GPCRs including CTR can phos-
phorylate PKA, a serine threonine kinase, through a cAMP-
dependent pathway. A detailed study into the interactions be-
tween CT and PKA have revealed how CT can promote an
EMT in prostate cancer cells. The action of PKA can be de-
termined by its discrete location and the duration of activation,
a spatiotemporal effect. A-kinase anchoring proteins
(AKAPs) provide this spatial specificity for PKA by tethering
an activating enzyme in different intracellular environments.
Thakkar, et al. hypothesised that CTR increases the metastatic
capability of prostate cancer cells by selectively activating
AKAP and indirectly influencing PKA.
Treatment with CT in PC3 cells causes an increase in inva-
sion and adhesion which can be abolished using Ht-31Pro, an
AKAP inhibitor. There are more than 50 different AKAPs,
and so, to identify which one is acting in CTR-induced PKA
activation, the group used siRNA to knockdown different
AKAPs to see which caused an inhibitory effect. By focusing
on just the AKAPs localised to the plasma membrane, they
found AKAP2 can reverse CT-induced invasion of prostate
cancer cells. Further evidence showed CT could cause in-
creases in proliferation, colony formation and orthotopic tu-
mours with bone metastasis, and all these effects could be
reversed with AKAP2 knockdown. Analysis of different pros-
tatic tissues with immunohistochemistry found that AKAP2
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levels are barely detectable in benign prostatic human tissue
but becomes visible in localised prostate cancer and signifi-
cantly higher in metastatic prostate cancer [34•].
Many peptide receptors contain PDZ-binding motifs
which are a common mechanism for cancer metastasis.
Aljameeli, et al. have recently investigated the PDZ motif
in CTR to see if this is an appropriate mechanism for
CTR in prostate cancer metastasis. By mutating the do-
main in different prostate cancer cell lines, they found that
it is required for tight junction stability, and that its dele-
tion reversed a 2.5-fold increase in invasion seen in pros-
tate cancer cells stimulated with CT. This mutation has no
effect on cAMP pathway activation suggesting ulterior
signaling pathways may be utilised after CTR activation.
Yeast 2 hybrid complementation is a method for identify-
ing important protein-protein interactions; the strongest
signal the group found was on zona occludens 1 (ZO-1).
This is novel finding showing CTR may act with ZO-1, a
key protein in tight junction regulation. In vivo studies
showed deletion of PDZ-binding domain on CTR pro-
duces no metastasis in the femur which were fourfold
more frequent in control mice [35••]. The relationship
between CT and ZO-1 could be further investigated in
the future to provide additional evidence of its vital role
in the promotion of prostate cancer cell metastasis. It is
also interesting to note that RAMP3 contains a PDZ-
binding motif, and therefore these mechanisms could be
mirrored in other calcitonin peptides.
Prostate Cancer and Metastasis: Calcitonin
Gene-Related Peptide
Many different neuropeptides including CGRP are
expressed in the prostate gland in both autonomic and sen-
sory nerves and in neuroendocrine cells. Neuroendocrine
cells are known to differentiate more frequently in prostate
cancer compared with many other cancers and correlates
with tumour progression [36]. It has long been known that
CGRP can increase the invasive and migratory capacity of
prostate cancer cells by 30–40% in vitro and that serum
levels correlate with prostate cancer progression in human
patients [37, 38]. However more recently studies associated
with RAMP1 may provide evidence of the CGRP receptor
promoting prostate cancer and metastasis to the bone.
NKX3.1 is a prostate specific transcription factor that
functions in prostate development as well as tumour pro-
gression. NKX3.1 deletion in mice leads to formation of
premalignant lesions in prostate. Using ChIP-seq, Logan,
et al. could identify RAMP1 as a novel NKX3.1 target gene.
Analysis using Oncomine, a cancer-specific bioinformatics
database, found RAMP1 to be significantly upregulated in
prostate cancer when compared with other cancers
including the breast, bladder, liver, lung and pancreatic
(P = 6.36 × 10−47). RAMP1 knockdown in two different
prostate cancer cell lines showed decreases in proliferation,
colony formation and numbers of cells in S phase of the cell
cycle. In vivo, it produced smaller tumour sizes and reduced
proliferation of cells. Downstream analysis found that
levels of phosphorylated ERK1/2 were also reduced,
linking RAMP1 to the MAPK pathway [39].
The Role of the Calcitonin Family in Bone
Microenvironment
A comprehensive review by Cornish, et al. has detailed
the extensive role of the calcitonin peptides and their re-
ceptors in the regulation of bone metabolism. This review
highlights findings from the past 30 years that show how
calcitonin itself acts by lowering calcium levels in the
blood triggered by inhibition of bone resorption, and the
anti-resorptive properties of this peptide led to the discov-
ery of its therapeutic uses in diseases associated with high
bone turnover. More detailed studies have found that CT,
CGRP and amylin can inhibit osteoclast motility and
cause quiescence through a cAMP-dependent mechanism
[40, 41]. However, CT is unique in its ability to alter
intracellular calcium leading to osteoclast retraction, and
this is believed to be achieved through cAMP-PKA me-
diated pathways that result in the disruption of cytoskele-
tal organization and alterations to cellular polarity of os-
teoclasts [42, 43]. CT can also act dose-dependently on
mouse bone marrow cultures to induce the formation of
multinucleated TRAP-positive cells at a much higher po-
tency than CGRP and amylin [1].
Adrenomedullin has not been found to play a role in
inducing hypocalcemia or inhibiting osteoclast function in
normal physiology. Nevertheless, it does have a role to
play in osteoblast act ivi ty and bone format ion.
Proliferation of osteoblasts in vitro can be stimulated by
AM, CGRP and amylin, and in vivo studies have shown
this can trigger bone formation. AM has been described
previously as a potent osteoblast mitogen, due to its abil-
ity to increase proliferation at physiological concentra-
tions of 10−12 M. AM and amylin at equipotency can
dramatically increase bone formation and mineralized
bone area, approximately threefold when injected daily
into the hemicalvariae of adult mice [44]. Other in vivo
models have found AM to have a profound effect on bone
mass, increasing mouse tibial cortical width and trabecu-
lar bone volume by 21 and 45%, respectively. A signifi-
cant increase in thickness of the epiphyseal growth plate
was also found compared with control animals, leading to
the conclusion that AM has a strong anabolic effect which
may link to the normal regulation of bone mass [45].
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Prostate Cancer and the Bone Microenvironment:
Adrenomedullin
An important mechanism through which tumour cells sur-
vive is their interaction with the bone microenvironment
once metastasis has occurred. By signalling to the sur-
rounding stroma, tumours are capable of progressing into
a more aggressive phenotype. It is therefore apt to inves-
tigate whether the calcitonin family of peptides and their
receptors play a role in influencing the bone microenvi-
ronment to promote tumourigenesis. Due to its potent ef-
fect on osteoblasts, AM could be capable of aiding tu-
mour growth when metastasis to the bone has already
occurred. To investigate this, Siclari et al. used a novel
ex vivo model to co-culture breast cancer cells with mice
calvarial bone. Tumour activity was then monitored by
analysing changes in human tumour and mouse bone gene
expression with qPCR. Tumour activity was significantly
increased when treating with AM, and this was reversed
with AM antagonists. Increases in expression of RANKL
were seen in these co-cultures but it was found AM does
not regulate this alone, which is consistent with data
showing its lack of effect on osteoclasts. However, breast
cancer cells co-cultured with the bone cause a decrease in
bone RANKL and an increase in tumour cell RANKL
expression. This effect is reversed by the treatment of
AM, so RANKL levels are higher in bone than in tumour
cells, this can be abolished using an AM antagonist.
Previous studies of a vicious cycle in bone and breast
cancer implicated PTHrP but expression of this peptide
remained unchanged in all conditions leading to the con-
clusion that PTHrP is not responsible [46•].
Results of this investigation suggest that AM can increase
tumour-induced osteolysis by altering localised production of
RANKL, and that this change can be blocked using an AM
antagonist. Nevertheless, there is much evidence that addition
of AM to bone cultures does not stimulate osteoclast prolifer-
ation. The authors suggest that AM must be stimulating
RANKL expression either by its effect on osteoblasts or by
acting on tumour cells to release signals that then act on
RANKL. They reason that AM has been shown to increase
IL-6 expression in mesenchymal cells, but this has not been
studied in bone or cancer models. This role of AM in RANKL
expression and bone metastasis remains ongoing, and further
studies in prostate cancer could reveal the mechanism behind
this [46•].
Prostate Cancer and the Bone Microenvironment:
Calcitonin
Immunostaining of prostate cancer patient tissues shows sig-
nificant increases in CT in high grade prostatic intraepithelial
neoplasia and malignant acini of the prostate. However, in
bone metastasis of prostate cancer, there is intense cytoplas-
mic staining of CT, suggesting that it is secreted by tumour
cells after implanting in the bone, possibly to stimulate the
bone microenvironment. Immunofluorescent staining of both
CT and CTR shows only expression of either the ligand or
receptor in stages 2 and 3 of prostate cancer but that CT-CTR
co-expression is seen only in stage 4. This provides evidence
that the CT-CTR axis has a paracrine effect earlier in prostate
cancer but converts to an autocrine function after tumour me-
tastasis to the bone. CT-CTR expression is also increased
when comparing metastatic prostate tissue with localised sites
[47]. This is consistent with previous data that shows CT-CTR
expression acts to enhance prostate cancer growth and pro-
gression to metastasis [12].
Prostate Cancer and the Bone Microenvironment:
Calcitonin Gene-Related Peptide
The metastasis of prostate cancer to the bone can lead to bone
pain in many patients, and this is a topic of much discussion in
the literature. Studies investigating bone pain in prostate can-
cer also provide evidence of tumour cells acting on the sur-
rounding stromal cells to influence the bone microenviron-
ment. Canine prostate cancer cells were labelled with GFP
before being injected into mouse femurs. An anti-CGRP anti-
body was then used to tag CGRP-positive sensory nerves. In
control animals, nerves grow along the long axis of the bone,
and as single fibres with a linear morphology however are
compared with tumour-bearing mice, these fibres were grown
in a disorganised manner with a thick fibre density and
sprouting directly from prostate cancer cell colonies. These
CGRP+ fibres also expressed TrkA, a receptor for Nerve
Growth Factor (NGF) which promotes growth of new fibres
in developing and adult animals. Interestingly, prostate cancer
cells do not express NGF, suggesting that their implantation
into the bone causes a tumour-associated effect on stromal
cells. Further staining using DAPI for all nuclear cells and
GFP for prostate cancer cells showed that up to 90% of the
cells in prostate cancer colonies were stromal rather than tu-
mour cells [48].
The prostate gland contains both autonomic and sensory
neurons as well as neuroendocrine cells that secrete neuropep-
tides such as CGRP, and it has been reported previously that in
prostate tumours, these cells often occur near highly prolifer-
ative cells. It has also been shown that RAMP1 knockdown in
prostate cancer cells causes increases in MAPK, ERK1/2 and
IL-6 [39]. Therefore, the presence of CGRP+ nerves in pros-
tate cancer models indicates that secretion of CGRP can in-
fluence the bone microenvironment. Tumour-associated fac-
tors, like CGRP, can trigger the promotion of pathological
sprouting of sensory neurons by increasing NGF expression.
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Conclusions
Findings over the past 5 years have provided much evi-
dence for the role of the calcitonin family of peptides in
prostate cancer and aiding metastasis to the bone. Not
only do they seem to exert their effect to promote tumor-
igenesis but are also able to alter the bone microenviron-
ment to further prostate cancer progression. Although AM
is known to have a potent effect on bone physiology, there
could still be further study into how it can affect both
bone and tumour cells during prostate cancer metastasis.
There is a clear gap in the literature investigating how
AM is interacting with the bone microenvironment either
directly or indirectly. This information would be very use-
ful when focusing on AM as a therapeutic target in pros-
tate cancer, especially in more advanced stages of the
disease. This would provide a precedent for the investiga-
tion of AM2 (Intermedin) which has already been linked
with prostate cancer in clinical studies, and a further un-
derstanding of this peptide would be very beneficial in
this field of research. RAMP1 has now also been impli-
cated as a major driver in prostate cancer, and so, linking
this to CGRP will hopefully prompt researchers to look at
this peptide in more detail. There also exist gaps in the
literature when assessing the role of calcitonin in prostate
cancer. With recent studies providing more evidence, it is
clear that calcitonin is another target that must be inves-
tigated. In addition, to successfully determine each of
these peptides’ influence on prostate cancer and metasta-
sis, it is imperative to consider their individual receptor
components as targets themselves. It is therefore certain
that future research into the calcitonin family of peptides
and their receptors will eventually lead to identification of
prognostic markers and potential therapeutic targets that
will ultimately increase the life expectancy of prostate
cancer patients dramatically.
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